| scholarly article | Q13442814 |
| P2093 | author name string | Zuoshang Xu | |
| Cheolwha Jung | |||
| Cynthia M J Higgins | |||
| P2860 | cites work | Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis | Q48555976 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | amyotrophic lateral sclerosis | Q206901 |
| P304 | page(s) | 535-545 | |
| P577 | publication date | 2002-11-01 | |
| P1433 | published in | Journal of Neurochemistry | Q6295643 |
| P1476 | title | Mitochondrial electron transport chain complex dysfunction in a transgenic mouse model for amyotrophic lateral sclerosis | |
| P478 | volume | 83 |
| Q42944130 | 2-Phenylethylamine, a constituent of chocolate and wine, causes mitochondrial complex-I inhibition, generation of hydroxyl radicals and depletion of striatal biogenic amines leading to psycho-motor dysfunctions in Balb/c mice |
| Q26774824 | ALS Patient Stem Cells for Unveiling Disease Signatures of Motoneuron Susceptibility: Perspectives on the Deadly Mitochondria, ER Stress and Calcium Triad |
| Q24792140 | ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes |
| Q38552413 | AMPK Signalling and Defective Energy Metabolism in Amyotrophic Lateral Sclerosis |
| Q39014987 | Alternative Fuels in Epilepsy and Amyotrophic Lateral Sclerosis. |
| Q51801091 | Amyotrophic lateral sclerosis, enteral nutrition and the risk of iron overload. |
| Q89964362 | Antioxidant Alternatives in the Treatment of Amyotrophic Lateral Sclerosis: A Comprehensive Review |
| Q41063803 | Bioenergetic Failure in Rat Oligodendrocyte Progenitor Cells Treated with Cerebrospinal Fluid Derived from Multiple Sclerosis Patients |
| Q28084373 | Calcium dysregulation links ALS defective proteins and motor neuron selective vulnerability |
| Q22337443 | Caloric restriction transiently improves motor performance but hastens clinical onset of disease in the Cu/Zn-superoxide dismutase mutant G93A mouse |
| Q40233562 | Cerebrospinal Fluid from Sporadic Amyotrophic Lateral Sclerosis Patients Induces Mitochondrial and Lysosomal Dysfunction. |
| Q59544343 | Chapter 11 Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis |
| Q57261217 | Chapter 14 Familial amyotrophic lateral sclerosis |
| Q59544323 | Chapter 4 Molecular mechanisms of motor neuron degeneration in amyotrophic lateral sclerosis |
| Q45213388 | Cytochrome c association with the inner mitochondrial membrane is impaired in the CNS of G93A-SOD1 mice. |
| Q55114619 | Dietary supplementation with ketoacids protects against CKD-induced oxidative damage and mitochondrial dysfunction in skeletal muscle of 5/6 nephrectomised rats. |
| Q36934610 | Different regulation of wild-type and mutant Cu,Zn superoxide dismutase localization in mammalian mitochondria |
| Q47265472 | Disturbed Glucose Metabolism in Rat Neurons Exposed to Cerebrospinal Fluid Obtained from Multiple Sclerosis Subjects |
| Q34030539 | Effects of natural antioxidants in neurodegenerative disease. |
| Q52651163 | Energy metabolism in ALS: an underappreciated opportunity? |
| Q91811242 | Existing and Emerging Metabolomic Tools for ALS Research |
| Q44441857 | Factors controlling the uptake of yeast copper/zinc superoxide dismutase into mitochondria. |
| Q44810798 | Folate deficiency and homocysteine induce toxicity in cultured dorsal root ganglion neurons via cytosolic calcium accumulation |
| Q44683629 | Impact of mitochondrial inhibition on excitability and cytosolic Ca2+ levels in brainstem motoneurones from mouse |
| Q26766040 | Impaired Autophagy and Defective Mitochondrial Function: Converging Paths on the Road to Motor Neuron Degeneration |
| Q35673759 | Induction of rat hepatic mitochondrial membrane permeability transition pore opening by leaf extract of Olax subscorpioidea. |
| Q38518708 | Informatics-assisted protein profiling in a transgenic mouse model of amyotrophic lateral sclerosis. |
| Q57204416 | Inhibition of Chaperone Activity Is a Shared Property of Several Cu,Zn-Superoxide Dismutase Mutants That Cause Amyotrophic Lateral Sclerosis |
| Q39361708 | Insights into the mechanisms of copper dyshomeostasis in amyotrophic lateral sclerosis |
| Q33858257 | Measures of bulbar and spinal motor function, muscle innervation, and mitochondrial function in ALS rats |
| Q33358054 | Messenger RNA oxidation occurs early in disease pathogenesis and promotes motor neuron degeneration in ALS |
| Q39101800 | Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments |
| Q51736520 | Metabolic Reprogramming in Amyotrophic Lateral Sclerosis. |
| Q64966837 | Metabolic and Stress Response Changes Precede Disease Onset in the Spinal Cord of Mutant SOD1 ALS Mice. |
| Q24683677 | Misfolded CuZnSOD and amyotrophic lateral sclerosis |
| Q37999478 | Misfolded SOD1 and ALS: zeroing in on mitochondria |
| Q34139970 | Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS |
| Q36565597 | Mitochondria in amyotrophic lateral sclerosis: a trigger and a target |
| Q39016389 | Mitochondrial Dysfunction and Biogenesis in Neurodegenerative diseases: Pathogenesis and Treatment. |
| Q98224396 | Mitochondrial Dysfunction, Neurogenesis, and Epigenetics: Putative Implications for Amyotrophic Lateral Sclerosis Neurodegeneration and Treatment |
| Q45306770 | Mitochondrial NAD+-linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease. |
| Q46087823 | Mitochondrial alterations in transgenic mice with an H46R mutant Cu/Zn superoxide dismutase gene |
| Q97884849 | Mitochondrial calcium signalling and neurodegenerative diseases |
| Q34551000 | Mitochondrial degeneration in amyotrophic lateral sclerosis. |
| Q34103782 | Mitochondrial dysfunction and intracellular calcium dysregulation in ALS |
| Q37352307 | Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes motor neuron degeneration: prevention by mitochondrial-targeted antioxidants |
| Q27013585 | Mitochondrial dysfunction in amyotrophic lateral sclerosis - a valid pharmacological target? |
| Q37954547 | Mitochondrial dysfunction in familial amyotrophic lateral sclerosis |
| Q37432118 | Mitochondrial function, morphology, and axonal transport in amyotrophic lateral sclerosis |
| Q36444334 | Mitochondrial involvement in amyotrophic lateral sclerosis: trigger or target? |
| Q47923054 | Mitochondrial protein oxidation in yeast mutants lacking manganese-(MnSOD) or copper- and zinc-containing superoxide dismutase (CuZnSOD): evidence that MnSOD and CuZnSOD have both unique and overlapping functions in protecting mitochondrial proteins |
| Q36573336 | Molecular biology of amyotrophic lateral sclerosis: insights from genetics |
| Q35196302 | Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals |
| Q38179996 | Neuronal calcium signaling: function and dysfunction |
| Q62785679 | Neuronal glucose metabolism is impaired while astrocytic TCA cycling is unaffected at symptomatic stages in the hSOD1G93A mouse model of amyotrophic lateral sclerosis |
| Q50904589 | Neuroprotective Effect of Human Adipose Stem Cell-Derived Extract in Amyotrophic Lateral Sclerosis. |
| Q33783000 | New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders |
| Q35749657 | Overexpression of CCS in G93A-SOD1 mice leads to accelerated neurological deficits with severe mitochondrial pathology |
| Q40353868 | PGC-1α Silencing Compounds the Perturbation of Mitochondrial Function Caused by Mutant SOD1 in Skeletal Muscle of ALS Mouse Model |
| Q24336201 | Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels |
| Q35166545 | Peroxisome proliferator activator receptor gamma coactivator-1alpha (PGC-1α) improves motor performance and survival in a mouse model of amyotrophic lateral sclerosis |
| Q30494108 | Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. |
| Q25256714 | Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation |
| Q47372795 | Proteinopathies and OXPHOS dysfunction in neurodegenerative diseases |
| Q38058054 | Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery. |
| Q55266660 | Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy. |
| Q27026894 | Redox regulation in amyotrophic lateral sclerosis |
| Q37717433 | Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice. |
| Q37836981 | Review: The role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis. |
| Q33819255 | Role of mitochondria in mutant SOD1 linked amyotrophic lateral sclerosis |
| Q35802837 | Seeking homeostasis: temporal trends in respiration, oxidation, and calcium in SOD1 G93A Amyotrophic Lateral Sclerosis mice |
| Q37048150 | Small peptides against the mutant SOD1/Bcl-2 toxic mitochondrial complex restore mitochondrial function and cell viability in mutant SOD1-mediated ALS |
| Q92534754 | Spinal Cord Metabolic Signatures in Models of Fast- and Slow-Progressing SOD1G93A Amyotrophic Lateral Sclerosis |
| Q73322228 | Stimulation‐Induced Mitochondrial [Ca2+] Elevations in Mouse Motor Terminals: Comparison of Wild‐Type with SOD1‐G93A |
| Q34808701 | The effect of SOD1 mutation on cellular bioenergetic profile and viability in response to oxidative stress and influence of mutation-type. |
| Q38577066 | The interplay between metabolic homeostasis and neurodegeneration: insights into the neurometabolic nature of amyotrophic lateral sclerosis. |
| Q36218731 | The mitochondrial calcium regulator cyclophilin D is an essential component of oestrogen-mediated neuroprotection in amyotrophic lateral sclerosis |
| Q35976264 | The role of creatine in the management of amyotrophic lateral sclerosis and other neurodegenerative disorders |
| Q36521932 | The role of mitochondria in inherited neurodegenerative diseases |
| Q24548966 | Translational control by neuroguidin, a eukaryotic initiation factor 4E and CPEB binding protein |
| Q37478060 | UCP2 overexpression worsens mitochondrial dysfunction and accelerates disease progression in a mouse model of amyotrophic lateral sclerosis |
| Q38178758 | Vitamin D as a potential therapy in amyotrophic lateral sclerosis |
| Q42730688 | What is "Hyper" in the ALS Hypermetabolism? |
Search more.